呼吸重症监护病房接受血栓预防患者的出血及危险因素:一项队列研究的二次数据分析
本研究为单中心前瞻性队列的二次数据分析,纳入2014年8月1日至2020年12月31日北京朝阳医院RICU收治的931例患者,随访至出院。715例(76.8%)为高出血风险,其余为低风险;9.2%(86/931)发生大出血,两组间无显著差异(p=0.601)。高出血风险患者结局较差,包括死亡率更高和住院时间更长。大出血的独立危险因素包括APACHE II评分≥15、侵袭性肺曲霉病、治疗剂量抗凝、体外膜氧合和连续性肾脏替代治疗;非出血相关输血似乎是大出血的独立保护因素(OR 0.099,95%CI 0.045-0.218,p<0.001)。
要点
- 931例RICU患者中76.8%被第9版ACCP指南评为高出血风险,但高、低风险组大出血发生率无显著差异(p=0.601)。
- 大出血的独立危险因素包括APACHE II评分≥15、侵袭性肺曲霉病、治疗剂量抗凝、体外膜氧合和连续性肾脏替代治疗。
- 非出血相关输血似乎是大出血的独立保护因素(OR 0.099,95%CI 0.045-0.218,p<0.001)。
- 高出血风险患者死亡率更高、住院时间更长。
- 第9版ACCP出血风险评估模型可能不适用于RICU患者,建立适用于所有RICU患者的出血风险评估模型仍是挑战。
适用人群与场景
- 2014年8月1日至2020年12月31日北京朝阳医院呼吸重症监护病房(RICU)收治的患者,随访至出院。
研究设计与关键结果
- 研究类型:单中心前瞻性队列研究的二次数据分析;样本量931例;人群:RICU患者。
- 715例(76.8%)为高出血风险,其余为低风险;9.2%(86/931)发生大出血,两组间无显著差异(p=0.601)。
- 高出血风险患者结局较差,包括死亡率更高和住院时间更长。
- 大出血的独立危险因素:APACHE II评分≥15、侵袭性肺曲霉病、治疗剂量抗凝、体外膜氧合、连续性肾脏替代治疗。
- 非出血相关输血似乎是大出血的独立保护因素(OR 0.099,95%CI 0.045-0.218,p<0.001)。
证据类型、等级与局限
- 证据类型:单中心前瞻性队列研究的二次数据分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 第9版ACCP出血风险评估模型可能不适用于RICU患者,作者认为建立适用于所有RICU患者的出血风险评估模型仍是挑战。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To verify whether the bleeding risk assessment guidelines from the 9th American College of Chest Physicians (ACCP) are prognostic for respiratory intensive care unit (RICU) patients and to explore risk factors for hemorrhages, we conducted a secondary data analysis based on our previously published cohort study of venous thromboembolism.
PATIENTS AND METHODS: We performed a secondary data analysis on the single-center prospective cohort from our previous study. Patients admitted to the RICU at Beijing Chao-Yang Hospital from August 1, 2014 to December 31, 2020 were included and followed up until discharge.
RESULTS: The study enrolled 931 patients, of which 715 (76.8%) were at high risk of bleeding, while the remaining were at low risk. Of the total, 9.2% (86/931) suffered major bleeding, and no significant difference was found between the two risk groups (p = 0.601). High-risk patients had poor outcomes, including higher mortality and longer stays. Independent risk factors for major bleeding were APACHE II score ≥ 15; invasive pulmonary aspergillosis; therapeutic dose of anticoagulants; extracorporeal membrane oxygenation; and continuous renal replacement therapy. Blood transfusion not related to bleeding appeared to be an independent protective factor for major bleeding (OR 0.099, 95% CI 0.045-0.218, p < 0.001).
CONCLUSION: Bleeding risk assessment models from the 9th ACCP guidelines may not be suitable for patients in RICU. Building a bleeding risk assessment model that is suitable for patients in all RICUs remains a challenge. Trial registration ClinicalTrials.gov: NCT02213978.
参考来源
- Lyu WR, Tang X, Jin Y, et al. Hemorrhages and risk factors in patients undergoing thromboprophylaxis in a respiratory critical care unit: a secondary data analysis of a cohort study. J Intensive Care. 2024. PMID: 39473017. doi:10.1186/s40560-024-00756-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。